二甲双胍与2型糖尿病患者COVID-19易感性及结局的关联
该研究基于英国大型初级保健数据库开展倾向评分匹配队列研究,比较当前处方含二甲双胍(MF+)与不含二甲双胍(MF-)的2型糖尿病成人。结果显示,疑似/确诊COVID-19、确诊COVID-19及COVID-19相关死亡的校正风险比分别为0.85、0.80和0.87,均无统计学意义;阴性对照结局分析未提示未测量混杂。结论认为当前二甲双胍处方与COVID-19风险或相关死亡无关。
要点
- 当前二甲双胍处方与疑似/确诊COVID-19风险无显著关联。
- 二甲双胍与COVID-19相关死亡风险无显著关联。
- 阴性对照分析未提示未测量混杂,支持继续处方二甲双胍以改善血糖控制。
核心结论
- 当前二甲双胍处方与COVID-19风险或COVID-19相关死亡无关。
- 继续处方二甲双胍以改善血糖控制是安全的。
研究设计与样本
- 采用倾向评分匹配队列研究,设置活性对照,使用英国大型初级保健数据集。
- 比较当前处方二甲双胍及其他降糖药(MF+)与当前处方不含二甲双胍的降糖药(MF-)的2型糖尿病成人。
主要发现
- 疑似/确诊COVID-19的校正风险比为0.85(95%CI 0.67, 1.08)。
- 确诊COVID-19的校正风险比为0.80(95%CI 0.49, 1.30)。
- COVID-19相关死亡的校正风险比为0.87(95%CI 0.34, 2.20)。
- 阴性对照结局(背痛)分析未提示未测量混杂。
临床怎么用
- 对于2型糖尿病患者,不应因担心COVID-19风险而停用二甲双胍。
- 可继续处方二甲双胍以改善血糖控制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Diabetes has emerged as an important risk factor for mortality from COVID-19. Metformin, the most commonly prescribed glucose-lowering agent, has been proposed to influence susceptibility to and outcomes of COVID-19 via multiple mechanisms. We investigated whether, in patients with diabetes, metformin is associated with susceptibility to COVID-19 and its outcomes. RESEARCH DESIGN AND METHODS: We performed a propensity score-matched cohort study with active comparators using a large UK primary care dataset. Adults with type 2 diabetes patients and a current prescription for metformin and other glucose-lowering agents (MF+) were compared to those with a current prescription for glucose-lowering agents that did not include metformin (MF-). Outcomes were confirmed COVID-19, suspected/confirmed COVID-19, and associated mortality. A negative control outcome analysis (back pain) was also performed. RESULTS: There were 29 558 and 10 271 patients in the MF+ and MF- groups, respectively, who met the inclusion criteria. In the propensity score-matched analysis, the adjusted hazard ratios for suspected/confirmed COVID-19, confirmed COVID-19, and COVID-19-related mortality were 0.85 (95% CI 0.67, 1.08), 0.80 (95% CI 0.49, 1.30), and 0.87 (95% CI 0.34, 2.20) respectively. The negative outcome control analysis did not suggest unobserved confounding. CONCLUSION: Current prescription of metformin was not associated with the risk of COVID-19 or COVID-19-related mortality. It is safe to continue prescribing metformin to improve glycemic control in patients with.
引用
- Wang J, Cooper JM, Gokhale K, et al. Association of Metformin with Susceptibility to COVID-19 in People with Type 2 Diabetes. J Clin Endocrinol Metab. 2021. PMID: 33560344. doi:10.1210/clinem/dgab067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。